Combination of Ayurvedic and Modern medicine in treatment of early rheumatoid arthritis

Assessment of efficacy of methotrexate with ayurvedic preparation (Singhnad guggul, Rasna saptak kwath, Erand oil) versus methotrexate with placebo in early rheumatoid arthritis: an exploratory double-blind randomized placebo-controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063232

Enrollment

160

Registered

2024-02-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: M058- Other rheumatoid arthritis with rheumatoid factor Health Condition 3: M056- Rheumatoid arthritis with involvement of other organs and systems Health Condition 4: M059- Rheumatoid arthritis with rheumatoid factor, unspecified Health Condition 5: M060- Rheumatoid arthritis without rheumatoid factor

Interventions

Intervention1: Methotrexate Singhnad guggul Erand oil Rasnasapthak kwath Panchakola churna: Panchakola churna 2gm twice daily x 7days Erand oil 10-20ml x 5-7days( as decided by ayurvedic physician) Ta

Eligibility

Inclusion criteria

Inclusion criteria: age more than 18years, early RA within 1 year of diagnosis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
DAS28ESR =3.2 DAS28CRP =3.2Timepoint: Baseline and 24 weeks	—

Secondary

Measure	Time frame
DAS28ESR = 2.6 DAS28CRP = 2.6 ACR 20, 50, 70 RESPONSE EULAR RESPONSE HAQ-DI (Indian Version) ANY SYMPTOMATIC ADVERSE EVENT TLC = 4000/mm3 platelet = 1,00,000/mm3 AST/ALT = 80 IU/L Timepoint: Baseline & 24 weeks	—

Countries

India

Contacts

Public ContactPrativa Priyadarshani Sethi

All India Institute of Medical sciences, Rishikesh

drsvpai@yahoo.com9040502676

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026